Coffin 3 , (1)Division of Gastroenterology, University of British Columbia, BC, Canada, (2)The Ottawa Hospital, Ottawa, ON, Canada, (3)Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, (4)Department of Medicine, University of Alberta, Edmonton, AB, Canada, (5)University Health Network, Toronto, Ontario, Canada, (6)Department of Medicine, University of Toronto, Toronto, ON, Canada, (7)Haskayne School of Business, University of Calgary, AB, Canada, (8)Toronto Liver Center, Toronto, Ontario, Canada, (9)Pacific Gastroenterology Associates, Vancouver, BC, Canada, (10)Cisss Laurentides, St-Jerome, Clinique Mdicale Urbaine Du Quartier Latin, QC, Canada, (11)Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, (12)Mcmaster University, Hamilton, on, Canada, (13)Cit-De- La- Sant De Laval, Laval, QC, Canada, (14)Division of Gastroenterology, Health Sciences, Dalhousie University, NS, Canada, (15)National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, (16)Department of Medicine, McGill University Health Centre, Westmount, QC, Canada Background: Although Canada has a universal health care system, this does not include prescription drug benefits and provincial drug coverage formulary is variable
Conway, L
The primary sources for this report include: Recalls (Enforcement Reports Database)+ The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or "not yet classified." While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls
doi: 10.1016/S0140-6736(80)92338-7 81 BischoffSCBernalWDasarathySMerliMPlankLDSchtzTet al
Circulation 2021;143:20072022
